Navigation Links
Denosumab reduces burden of giant-cell tumor of the bone
Date:9/21/2012

PHILADELPHIA Treatment with denosumab, a drug targeted against a protein that helps promote bone destruction, decreased the number of tumor giant cells in patients with giant-cell tumor of the bone, and increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"Giant-cell tumor of the bone is a rare tumor that affects mostly young people," said Sant P. Chawla, M.D., director of the Santa Monica Oncology Center, Santa Monica, Calif. "Radical surgery is currently the only treatment option. In our study, the use of denosumab allowed patients to avoid radical surgery and prevented recurrence. We hope that in the future, its use may make it possible to avoid surgery completely."

Giant-cell tumor of the bone is a benign tumor characterized by giant cells that are positive for the protein RANK ligand, which helps promote bone destruction. Currently, the only treatment option for patients with giant-cell tumor of the bone is surgery. However, patients who undergo surgery often have recurrent disease or significant morbidity, such as amputation. In addition, 25 to 30 percent of patients with this tumor have to undergo joint replacements.

Chawla and colleagues conducted this phase II study to explore the mechanism of action of denosumab, an inhibitor of RANK ligand, in the treatment of giant-cell tumor of the bone.

Twenty adult patients with recurrent or unresectable giant-cell tumor of the bone were treated with subcutaneous denosumab every four weeks. After treatment, all 20 of the patients had a decrease in giant cells of 90 percent or greater, an indicator of a reduction of tumor burden. In addition, results indicated that 65 percent of the patients had new bone growth in areas where the RANK ligand had previously caused bone destruction.

"A majority of patients with giant-cell tumor of the bone are young and have to get joint replacements, which last 15 to 20 years before a repeat surgery is needed," Chawla said. "Now, we hopefully can do minimal surgery, avoiding a joint replacement and recurrence."

One of the next steps in evaluating denosumab for giant-cell tumor of the bone is a much larger, multinational study that is currently enrolling patients. In addition, Chawla hopes to evaluate the use of denosumab as a presurgery, or neoadjuvant, treatment as well.

"In the future we hope to investigate giving the drug prior to surgery to see the effect it has, then remove the tumor and evaluate the pathological response," Chawla said.

This study was funded by Amgen.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
2. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
3. Automated breast ultrasound dramatically reduces physician interpretation time
4. NIH study finds sigmoidoscopy reduces colorectal cancer rates
5. Surgical removal of abdominal fat reduces skin cancer in mice
6. Long-term ICS use reduces pleural effusion in patients with CAP
7. Regional anesthesia reduces complications and death for hip fracture patients
8. Surgical sling reduces risk of weakened bladder control after prolapse surgery, U-M study says
9. Single embryo transfer reduces the risk of perinatal mortality in IVF
10. HPV vaccine reduces infection, even in unvaccinated
11. HIV drug reduces graft-vs.-host disease in bone marrow transplant patients, Penn study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Dr. Ronald E. Hawkins, vice president ... of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean ... Dr. Bell comes to Liberty from the Ohio University Heritage College of Osteopathic ...
(Date:2/24/2017)... ... , ... With millions of Americans and people worldwide struggling ... are aware of our options and are empowered with strength and information throughout ... its newest edition of "Vision and Hearing" in USA Today, that will educate ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... With ProGlass ... Cut Pro X . Users have total control over position, rotation, distortion, edge softness, ... all within Final Cut Pro X. , With ProGlass Prism users are given the ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) ... You See” body image mannequin art competition. Selected from 15 submissions from around the ... revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. ...
(Date:2/24/2017)... Fair Lawn, NJ (PRWEB) , ... February 24, ... ... with robust marketing services, which specializes in thought leadership , media ... email marketing campaigns and services that will be powered through Act-On, an intuitive ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... Craig , M.D., Ph.D., as President and Chief Executive Officer ... 20, 2017. Dr. Craig succeeds Richard Love , interim ... company,s Board of Directors.  Dr. Craig has over 20 years ... the US and Europe . ...
(Date:2/27/2017)... N.J. and PETACH TIKVAH, Israel ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... appointments of June S. Almenoff , M.D., Ph.D., ... to its Board of Directors.  "Dr. ... executives whose appointments come at an exciting time for ...
(Date:2/27/2017)... , Feb 27, 2017 Period October – December ... Operating result amounted to SEK -16.4 (-6.4) million ... per share (-0.22) before and after dilution Cash flow from ... ... to SEK 0.4 (0.4) million Operating result amounted to SEK ...
Breaking Medicine Technology: